Enhanced enfortumab vedotin sensitivity in a cisplatin-resistant bladder cancer model. Tobe T, Teishima J, Hara T, Shiraishi Y, et al. PLoS One 2026;21:e0361593.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tobe T, Teishima J, Hara T, Shiraishi Y, et al. Enhanced enfortumab vedotin sensitivity in a cisplatin-resistant bladder cancer model. PLoS One 2026;21:e0361593.
PMID: 42955934